

NO: 6 1998

K 982837

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92. All data included in this document is accurate and complete to the best of KSEA's knowledge.

Applicant: Karl Storz Endoscopy - America, Inc.
600 Corporate Pointe Drive
Culver City, CA 90230
(310) 410-2769

Contact: Kevin Kennan
Senior Regulatory Affairs Specialist


Device Identification: Common Name:
Neuroendoscope

Trade Name: (optional)
Karl Storz GAAB Neuroendoscope and CHAVANTES-ZAMORANO Neuro-endoscope Sets

Indication: The KSEA GAAB Neuroendoscope and CHAVANTES-ZAMORANO Neuro-endoscope Sets are intended for use by qualified surgeons for viewing the ventricles of the brain and performing diagnostic and therapeutic procedures.

Device Description: The Karl Storz GAAB Neuroendoscope and CHAVANTES-ZAMORANO Neuro-endoscope Sets are manually operated surgical devices. The body contact portions of the KSEA GAAB Neuroendoscope and CHAVANTES-ZAMORANO Neuro-endoscope Sets are composed of surgical grade stainless steel and medical grade silicone, which are commonly used in medical devices for a wide range of applications and have a long history of biocompatibility for human use.

Substantial Equivalence: The Karl Storz GAAB Neuroendoscope and CHAVANTES-ZAMORANO Neuro-endoscope Sets are substantially equivalent to the predicate devices since the basic features and intended uses are the same.

Signed: 
Kevin Kennan
Senior Regulatory Affairs Specialist

000086



NOV 6 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Kevin Kennan
Senior Regulatory Affairs Specialist
Karl Storz Endoscopy
600 Corporate Pointe
Culver City, California 90230-7600

Re: K982837
Trade Name: KSEA GAAB Neuroendoscope and CHAVANTES-ZAAMORANO
Neuroendoscope
Regulatory Class: II
Product Code: GWG
Dated: August 07, 1998
Received: August 12, 1998

Dear Mr. Kennan:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read 'C. Witten', is written over the typed name.

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K 982837

Device Name: KSEA GAAB Neuroendoscope and CHAVANTES-ZAMORANO
Neuroendoscope Sets

Indications for Use: These instruments are manually operated surgical devices intended for use by qualified surgeons for viewing the ventricles of the brain and performing diagnostic and therapeutic procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

Division of General Restorative Devices

510(k) Number

K 982837

Prescription Use: X

(Per 21 CFR 801.109)

OR Over-The-Counter Use: _____

(Optional Format 1-2-96)

000003